Citicoline and COVID-19: vis-à-vis conjectured

Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barri...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-kuraishy, Hayder M., Al-Buhadily, Ali K., Al-Gareeb, Ali I., Alorabi, Mohammed, Hadi Al-Harcan, Nasser A., El-Bouseary, Maisra M., Batiha, Gaber El-Saber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9442587/
https://www.ncbi.nlm.nih.gov/pubmed/36063198
http://dx.doi.org/10.1007/s00210-022-02284-6
Descripción
Sumario:Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19.

Ejemplares similares